Booth 1664
Noville-sur-Mehaigne, Belgium
Vésale Bioscience fight antibacterial multi-resistant infections (AMR) with personalized phage therapy solutions:
1) We have developed a fast diagnostic tool Luminophage®, an automated Phagogram®, that will recommend in a couple of hours (instead of days/weeks) the optimal phages association to fight the specific patient’s bacteria.
2) We produce (GMP) a library of phages in advance and can deliver within 24-48h the selected phages as API for tailored magistral preparations.

This approach dramatically increases the success rate of AMR treatments and allows to treat acute and chronic infections at the hospital.

Vésale Bioscience is a Belgian biotech, created in 2018 as a spin-out of Vésale Pharma specialized in treatments of the microbiome. Vésale Bioscience is privately owned and is regularly looking for new investors (series A foreseen end 2023)

Vésale Bioscience has developed a broad scientific network, including the Queen Astrid Military Hospital (BE), Laboratory of Brussels University Hospitals (BE), Eliava Institute (Georgia), and benefits from grants of the Walloon Region to develop its innovative solutions for human and veterinary use.

Bacteriophage portfolio:
Our phage library targets difficult-to-treat infections caused by Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Klebsiella pneumoniae, bacteria that are responsible for 70% of AMR infections in EU & US